Abstract: The present disclosure is directed to the treatment of diseases or conditions involving the buildup of fatty tissues, such as obesity, metabolic syndrome, type II diabetes, etc. A composition containing a monoclonal antibody directed against gastric inhibitory polypeptide is administered. This results in a reduced rate of weight gain and a marked decrease in lipid synthesis and accumulation.

Abstract: The present disclosure is directed to the treatment of ischemic heart disease and clinical conditions associated with ischemic heart disease. A composition containing a monoclonal antibody directed against gastric inhibitory polypeptide is administered. This results in cardioprotective effects against acute myocardial infarction, such as a decrease in circulating triglycerides, total cholesterol, and low-density lipoproteins, and an increase in the ratio of high-density lipoprotein to total cholesterol.

Abstract: The present disclosure is directed to the treatment of diseases or conditions involving the buildup of fatty tissues, such as obesity, metabolic syndrome, type II diabetes, etc. A composition containing a monoclonal antibody directed against gastric inhibitory polypeptide is administered. This results in a reduced rate of weight gain and a marked decrease in lipid synthesis and accumulation.

Abstract: Systems and methods for operating an antenna providing a coverage area using beamforming and carrier aggregation techniques. The proposed system aims to optimize the use of carrier aggregation for beamforming systems. The system may include a beamforming module coupled to first array and second arrays of radiating elements, the first array being configured to provide wireless coverage on a first frequency carrier in a first coverage area, and the second array being configured to provide wireless coverage on a second frequency carrier in a second coverage area. The beamforming module may be configured to receive one or more indicators associated with one or more user equipments (UEs) in the coverage area. Based on the one or more indicators, the beam-forming module may be configured to dynamically adjust, in the RF domain, at least one of a location of the second coverage area and a size of the second coverage area.

Abstract: A combination of an antacid, alginate, and a histamine H2-receptor antagonist, and methods of using the same for providing fast and lasting relief of symptoms of episodic heartburn are provided.

Abstract: The present disclosure is directed to the treatment of diseases or conditions involving the buildup of fatty tissues, such as obesity, metabolic syndrome, type II diabetes, etc. A composition containing a monoclonal antibody directed against gastric inhibitory polypeptide is administered. This results in a reduced rate of weight gain and a marked decrease in lipid synthesis and accumulation.

Abstract: The present disclosure is directed to the treatment of diseases or conditions characterized by the buildup of fatty tissue, or hyperphagia, such as Prader-Willi syndrome, obesity, metabolic syndrome, type II diabetes, etc. A composition containing a monoclonal antibody directed against gastric inhibitory polypeptide is administered. This results in a reduced rate of weight gain, weight loss, and/or reduction in fatty tissue, and a marked decrease in lipid synthesis and accumulation.

Abstract: The present disclosure is directed to the treatment of diseases or conditions involving the buildup of fatty tissues, such as obesity, metabolic syndrome, type II diabetes, etc. A composition containing a monoclonal antibody directed against gastric inhibitory polypeptide is administered. This results in a reduced rate of weight gain and a marked decrease in lipid synthesis and accumulation.

Abstract: The present disclosure is directed to the treatment of diseases or conditions involving the buildup of fatty tissues, such as obesity, metabolic syndrome, type II diabetes, etc. A composition containing a monoclonal antibody directed against gastric inhibitory polypeptide is administered. This results in a reduced rate of weight gain and a marked decrease in lipid synthesis and accumulation.

Abstract: A toner includes a core including a homogenized mixture of a first polyester latex, a styrene/acrylate latex, and a compatibilizing agent latex that includes a graft polyester-styrene/acrylate copolymer and a shell that includes a polyester latex. A process includes (1) homogenizing a mixture to form a plurality of core particles, the mixture including a first polyester latex, a styrene/acrylate latex, and a compatibilizing agent latex comprising a graft polyester-styrene/acrylate copolymer and (2) adding a shell polyester latex to the plurality of core particles to form a plurality of core-shell structures.

Abstract: A method of forming toner particles includes aggregating a mixture of a latex, a wax, and an optional pigment to form pre-toner particles, and coalescing the pre-toner particles at a substantially constant target temperature selected within a range from about the glass transition temperature of the pre-toner particles to about 75° C., thereby creating toner particles having a substantially constant particle size distribution during the coalescing step.

Abstract: The present disclosure is directed to the treatment of diseases or conditions involving the buildup of fatty tissues, such as obesity, metabolic syndrome, type II diabetes, etc. A composition containing a monoclonal antibody directed against gastric inhibitory polypeptide is administered. This results in a reduced rate of weight gain and a marked decrease in lipid synthesis and accumulation.

Abstract: A method of forming toner particles includes aggregating a mixture of a latex, a wax, and an optional pigment to form pre-toner particles, and coalescing the pre-toner particles at a substantially constant target temperature selected within a range from about the glass transition temperature of the pre-toner particles to about 75° C., thereby creating toner particles having a substantially constant particle size distribution during the coalescing step.

Abstract: Queries to an enterprise data system based on discrete groups of servers may display the sets of data satisfying a query as if the query results originated from a single data repository. Further, queries within the system may efficiently search through a large set of satisfying records while accounting for data latency or system performance.

Abstract: An antenna orientation sensor, having a base, a pivoting support coupled to the base. An actuator operable to move the pivoting support through a calibration movement with respect to the base. A magnetic sensor on the pivoting support and a position sensor operable to sense the position of the pivoting support within the calibration movement.

Abstract: The present invention provides methods and compositions for the treatment and prevention of neoplasia by administering an effective amount of a NSAID in combination with an effective amount of an immunosuppressant agent. In particular, the present invention provides methods and compositions for the treatment and prevention of neoplasia by administering an effective amount of COX-2 inhibitor in combination with an effective amount of an immunosuppressant agent.

Abstract: An antenna orientation sensor, having a base, a pivoting support coupled to the base. An actuator operable to move the pivoting support through a calibration movement with respect to the base. A, for example, three axis magnetic sensor on the pivoting support and a position sensor operable to sense the position of the pivoting support within the calibration movement.

Abstract: Pharmaceutical proton pump inhibitor (PPI) medications and methods are disclosed for preventing and/or treating gastrointestinal disorders characterized by abnormalities in gastric acid secretion at anytime of the day or night without the need for food effect or to be taken with food. The medications comprise a PPI and a cholinergic agonist for inducing rapid onset of PPI action, for increasing the duration of PPI efficacy and for optimizing clinical PPI effectiveness that may be administered at any time of the day or night without food or on an empty stomach, and possibly on an as-needed or on demand basis. In carrying out the methods, a PPI and cholinergic agonist may be administered together as a single unitary dose in the form of a liquid or solid, or administered together, but separately as either liquids or solids or a combination thereof. Preferably, an oral solid dosage form of the present invention allows for release of a proton pump inhibitor at a pH of about 5 or higher, e.g., pH about 5.5, 6, 6.

Abstract: In one embodiment, this invention provides an antagonist of glucose-dependent insulinotropic polypeptide (GIP) consisting essentially of a 24 amino acid polypeptide corresponding to positions 7-30 of the sequence of GIP. In another embodiment, this invention provides a method of treating non-insulin dependent diabetes mellitus in a patient comprising administering to the patient an antagonist of glucose-dependent insulinotropic polypeptide (GIP). In yet another embodiment, this invention provides a method of improving glucose tolerance in a mammal comprising administering to the mammal an antagonist of glucose-dependent insulinotropic polypeptide (GIP).

Abstract: In one embodiment, this invention provides an antagonist of glucose-dependent insulinotropic polypeptide (GIP) consisting essentially of a 24 amino acid polypeptide corresponding to positions 7-30 of the sequence of GIP. In another embodiment, this invention provides a method of preventing and treating obesity and non-insulin dependent diabetes mellitus (Type II) in a patient comprising administering to the patient an antagonist of glucose-dependent insulinotropic polypeptide (GIP). In yet another embodiment, this invention provides a method of improving glucose tolerance in a mammal comprising administering to the mammal an antagonist of glucose-dependent insulinotropic polypeptide (GIP).